Teneligliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells

References

• Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13(1):7–18. doi:10.1111/j.1463-1326.2010.01306.x
   PubMed Web of Science ®Google Scholar
• Omar B, Ahren B. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes. 2014;63(7):2196–2202. doi:10.2337/db14-0052
   PubMed Web of Science ®Google Scholar
• Chen XW, He ZX, Zhou ZW, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42(10):999–1024. doi:10.1111/1440-1681.12455
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–2498. doi:10.1007/s00125-018-4729-5
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019;40:1–69. doi:10.1093/eurheartj/ehz486
   PubMed Web of Science ®Google Scholar
• Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1 alpha. Diabetes Care. 2010;33(7):1607–1609. doi:10.2337/dc10-0187
   PubMed Web of Science ®Google Scholar
• Huang CY, Shih CM, Tsao NW, et al. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol. 2012;167(7):1506–1519. doi:10.1111/j.1476-5381.2012.02102.x
   PubMed Web of Science ®Google Scholar
• Goda M, Kadowaki T. Teneligliptin for the treatment of type 2 diabetes. Drugs Today. 2013;49(10):615–629. doi:10.1358/dot.2013.49.10.2035882
   PubMed Web of Science ®Google Scholar
• Otsuki H, Kosaka T, Nakamura K, et al. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. Int Urol Nephrol. 2014;46(2):427–432. doi:10.1007/s11255-013-0552-6
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Marubayashi F, Yokota S, Katoh M, Iijima H. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies. Expert Opin Pharmacother. 2015;16(7):971–981. doi:10.1517/14656566.2015.1032249
   PubMed Web of Science ®Google Scholar
• Akashi N, Umemoto T, Yamada H, et al. 1096-P: DPP-4 inhibitor teneligliptin improves the vascular endothelial function via mechanism different from changes of EPCs levels and blood glucose metabolism. Diabetes. 2020;69(Supplement_1). doi:10.2337/db20-1096-P
   Google Scholar
• Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--A randomized placebo-controlled trial. Am Heart J. 2013;166:217–223 e211. doi:10.1016/j.ahj.2013.05.007
   PubMed Web of Science ®Google Scholar
• Makino H, Okada S, Nagumo A, et al. Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients. Diabetes Res Clin Pract. 2008;81(3):327–330. doi:10.1016/j.diabres.2008.05.012
   PubMed Web of Science ®Google Scholar
• Ip SH, Rittershaus CW, Healey KW, et al. Rapid enumeration of T lymphocytes by a flow-cytometric immunofluorescence method. Clin Chem. 1982;28(9):1905–1909. doi:10.1093/clinchem/28.9.1905
   PubMed Web of Science ®Google Scholar
• Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39(2):257–265. doi:10.1016/s0735-1097(01)01746-6
   PubMed Web of Science ®Google Scholar
• Harris RA, Nishiyama SK, Wray DW, Richardson RS. Ultrasound assessment of flow-mediated dilation. Hypertension. 2010;55(5):1075–1085. doi:10.1161/hypertensionaha.110.150821
   PubMed Web of Science ®Google Scholar
• Busso N, Wagtmann N, Herling C, et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol. 2005;166(2):433–442. doi:10.1016/s0002-9440(10)62266-3
   PubMed Web of Science ®Google Scholar
• Packer M. Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. Cardiovasc Diabetol. 2018;17(1):9. doi:10.1186/s12933-017-0648-x
   PubMedGoogle Scholar
• Janowski M. Functional diversity of SDF-1 splicing variants. Cell Adh Migr. 2009;3(3):243–249. doi:10.4161/cam.3.3.8260
   PubMed Web of Science ®Google Scholar
• Luo Q, Zhang B, Kuang D, Song G. Role of stromal-derived factor-1 in mesenchymal stem cell paracrine-mediated tissue repair. Curr Stem Cell Res Ther. 2016;11(7):585–592. doi:10.2174/1574888x11666160614102629
   PubMed Web of Science ®Google Scholar
• Lovshin JA, Rajasekeran H, Lytvyn Y, et al. Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1α(1-67) in patients with type 2 diabetes. Diabetes Care. 2017;40(8):1073–1081. doi:10.2337/dc17-0061
   PubMed Web of Science ®Google Scholar
• Aso Y, Jojima T, Iijima T, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34⁺CXCR4⁺ cells in patients with type 2 diabetes. Endocrine. 2015;50(3):659–664. doi:10.1007/s12020-015-0688-5
   PubMed Web of Science ®Google Scholar
• Dei Cas A, Spigoni V, Cito M, et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. Cardiovasc Diabetol. 2017;16(1):27. doi:10.1186/s12933-017-0503-0
   PubMedGoogle Scholar
• Park KS, Kwak S, Cho YM, et al. Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride. J Diabetes Investig. 2017;8(2):218–226. doi:10.1111/jdi.12572
   PubMed Web of Science ®Google Scholar
• Misra P, Lebeche D, Ly H, et al. Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1 alpha. J Nucl Med. 2008;49(6):963–969. doi:10.2967/jnumed.107.050054
   PubMed Web of Science ®Google Scholar
• Kubota Y, Miyamoto M, Takagi G, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27(11):1364–1370. doi:10.3346/jkms.2012.27.11.1364
   PubMed Web of Science ®Google Scholar
• Ayaori M, Iwakami N, Uto-Kondo H, et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013;2(1):e003277. doi:10.1161/jaha.112.003277
   PubMed Web of Science ®Google Scholar
• Nakamura K, Oe H, Kihara H, et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol. 2014;13(1):110. doi:10.1186/s12933-014-0110-2
   PubMedGoogle Scholar
• Ida S, Murata K, Betou K, et al. Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study. Cardiovasc Diabetol. 2016;15(1):153. doi:10.1186/s12933-016-0468-4
   PubMed Web of Science ®Google Scholar
• Kitao N, Miyoshi H, Furumoto T, et al. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Cardiovasc Diabetol. 2017;16(1):125. doi:10.1186/s12933-017-0607-6
   PubMedGoogle Scholar
• Tripolt NJ, Aberer F, Riedl R, et al. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial. Cardiovasc Diabetol. 2018;17(1):71. doi:10.1186/s12933-018-0716-x
   PubMedGoogle Scholar
• Matsubara J, Sugiyama S, Akiyama E, et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77(5):1337–1344. doi:10.1253/circj.cj-12-1168
   PubMed Web of Science ®Google Scholar
• Fadini GP, Bonora BM, Cappellari R, et al. Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes. J Clin Endocrinol Metab. 2016;101(2):748–756. doi:10.1210/jc.2015-3716
   PubMed Web of Science ®Google Scholar
• Fadini GP, Agostini C, Sartore S, Avogaro A. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis. 2007;194(1):46–54. doi:10.1016/j.atherosclerosis.2007.03.046
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi:10.1056/NEJMoa1501352
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi:10.1056/NEJMoa1307684
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi:10.1056/NEJMoa1305889
   PubMed Web of Science ®Google Scholar
• Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97(17):1695–1701. doi:10.1161/01.cir.97.17.1695
   PubMed Web of Science ®Google Scholar
• Title LM, Cummings PM, Giddens K, Nassar BA. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol. 2000;36(7):2185–2191. doi:10.1016/s0735-1097(00)00980-3
   PubMed Web of Science ®Google Scholar
• Maruhashi T, Higashi Y. Pathophysiological association between diabetes mellitus and endothelial dysfunction. Antioxidants. 2021;10(8). doi:10.3390/antiox10081306
   Web of Science ®Google Scholar
• Masoura C, Pitsavos C, Aznaouridis K, et al. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis. 2011;214(1):129–138. doi:10.1016/j.atherosclerosis.2010.10.008
   PubMed Web of Science ®Google Scholar
• Liao YF, Chen LL, Zeng TS, et al. Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes. Vasc Med. 2010;15(4):279–285. doi:10.1177/1358863x10367537
   PubMed Web of Science ®Google Scholar
• Brown CG, Kelen GD, Ashton JJ, Werman HA. The beta error and sample size determination in clinical trials in emergency medicine. Ann Emerg Med. 1987;16(2):183–187. doi:10.1016/s0196-0644(87)80013-6
   PubMed Web of Science ®Google Scholar
• Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol. 2007;49(7):741–752. doi:10.1016/j.jacc.2006.09.050
   PubMed Web of Science ®Google Scholar